Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections
Clinical proof-of-concept has been achieved for TRL1068 in a planned interim analysis based on completion of the second of three escalating dose groups 75% of...
Source: prnewswire.com